PROTOKOLwiki
COMPOUNDS / NOOTROPIC / ANIRACETAM
NOOTROPIC

ANIRACETAM

LOW RISK
BEST FOR:Cognition●●●●●●○○○○6/10
ANIRACETAM · DRAGANON · SARPUL · AMPAMET · MEMODRIN · RO-13-5057
NootropicRacetamAMPA ModulatorCognitive EnhancerAnxiolytic

A racetam-family nootropic that modulates AMPA and metabotropic glutamate receptors, used for cognitive enhancement and dementia support.

ROUTE / DOSAGE
LOW500mg
STANDARD750-1500mg
HIGH2000mg+
Note: Fat-soluble racetam; take with food for absorption. Clinical dose 1500mg/day divided.
CYCLE
1-3x daily no established cycle limit
BIOAVAILABILITY
~1% oral (extensive first-pass metabolism active metabolites)
ACTIVE DURATION
4-6h (subjective)
STORAGE
Room temperature dry away from light
HALF-LIFE
1-3 hours (plasma)
DURATION BREAKDOWN
Total4-6 hours
Onset30-90 min
Come up30-60 min
Peak1-2 hours
Offset1-3 hours
After effects2-4 hours
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Enhanced memory in cognitively impaired subjects
Improved focus and attention
Anxiolytic effects
Enhanced learning capacity
Neuroprotective activity
Improved mood
Facilitated cholinergic transmission
§ 02 — RISKS
Headache (common with racetam class)
Gastrointestinal distress including nausea
Insomnia when taken late in the day
Anxiety or irritability at higher doses
Potential dangerous interaction with MAOIs
§ 03 — INTERACTIONS
No interaction with your stack
VIEW STACK
AVOID · DANGEROUS
MAOIs
§ 04 — SCIENCE

Aniracetam has demonstrated memory-enhancing effects in animal models of cognitive impairment, including scopolamine-induced amnesia and TARP γ-8 knockout mice modeling ADHD. Clinical trials in elderly patients with mild to moderate Alzheimer's dementia showed aniracetam 1500 mg/day was significantly more effective than placebo at 4 and 6 months. However, multiple studies in neurologically healthy animals (mice, pigeons) found no cognitive enhancement, suggesting benefits are limited to impaired subjects. Evidence for amyloid-β plaque reduction is theoretical and based on mechanistic models rather than clinical demonstration. Overall, human clinical evidence is preliminary and limited to older trials in dementia populations.

§ 06 — SOURCES
[1]
Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders
pubmed.ncbi.nlm.nih.gov ↗
[2]
Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties
pubmed.ncbi.nlm.nih.gov ↗
[3]
Aniracetam: An Evidence-Based Model for Preventing Amyloid-β Plaques
pubmed.ncbi.nlm.nih.gov ↗
[4]
Aniracetam does not improve working memory in neurologically healthy pigeons
pubmed.ncbi.nlm.nih.gov ↗
[5]
Aniracetam Ameliorates ADHD Behavior in Adolescent Mice
pubmed.ncbi.nlm.nih.gov ↗
[6]
Aniracetam does not alter cognitive and affective behavior in adult C57BL/6J mice
pubmed.ncbi.nlm.nih.gov ↗
[7]
Aniracetam reverses memory impairment in rats
pubmed.ncbi.nlm.nih.gov ↗
[8]
Aniracetam improves behavioural responses and facilitates signal transduction
pubmed.ncbi.nlm.nih.gov ↗
[9]
PsychonautWiki - Aniracetam
psychonautwiki.org ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT